US stock futures flat after Wall St drops on Trump tariffs, soft jobs data
WAYNE, Pa. and ROCKVILLE, Md. - Avalo Therapeutics, Inc. (NASDAQ: NASDAQ:AVTX) has initiated a Phase 2 clinical trial named LOTUS for its investigational drug AVTX-009, targeting the treatment of hidradenitis suppurativa (HS), a painful chronic inflammatory skin condition. The first patient has been dosed, marking a significant step in the development of this potential therapy.
The randomized, double-blind, placebo-controlled trial will assess the safety and efficacy of two dose regimens of AVTX-009 in approximately 180 adults with moderate to severe HS. Participants in the study will be assigned to receive either one of the two doses of AVTX-009 or a placebo over a 16-week treatment period. The primary measure of success will be the proportion of subjects achieving a specified clinical response at the end of this phase.
AVTX-009 is a humanized monoclonal antibody that targets interleukin-1β (IL-1β), a key player in the inflammatory process associated with HS. By neutralizing the activity of IL-1β, the drug aims to address the underlying cause of the disease. HS is characterized by painful nodules, abscesses, and tunnels in areas of the body such as the armpits, groin, and buttocks, significantly affecting individuals' quality of life.
The trial will also evaluate secondary outcomes, including the proportion of patients achieving different levels of clinical response and changes from baseline in various HS severity scores and pain assessments. The development of anti-drug antibodies, along with the safety and tolerability of the treatment, will be monitored throughout the study.
Avalo Therapeutics, specializing in the treatment of immune dysregulation, anticipates releasing topline results from the LOTUS trial in 2026. The trial's registration details can be found on the clinicaltrials.gov website under the identifier NCT06603077.
The press release statement from Avalo Therapeutics serves as the basis for this information. It should be noted that while the company has expressed confidence in the potential of AVTX-009 to become a leading treatment option for HS, these are forward-looking statements subject to significant risks and uncertainties.
In other recent news, Avalo Therapeutics has regained compliance with Nasdaq's Market Value of Listed Securities Standard, a significant development following a previous notification of non-compliance. The biopharmaceutical company has also initiated its phase 2 LOTUS trial for the treatment of hidradenitis suppurativa, a development that has been commended by Oppenheimer, who maintained an Outperform rating on the company.
In addition to these developments, Avalo Therapeutics has made amendments to its equity incentive and employee stock purchase plans, which have been approved by its stockholders. The company has also welcomed Mittie Doyle as its new Chief Medical Officer and Paul Varki as its new Chief Legal Officer, appointments that are expected to enhance the company's strategic capabilities.
Avalo Therapeutics has begun its Phase 2 clinical trial for the treatment of hidradenitis suppurativa, a chronic inflammatory skin condition. The trial will test the efficacy and safety of the company's drug candidate, AVTX-009. This trial, along with the company's recent strategic developments, have led to an Outperform rating from Oppenheimer. These are among the recent developments for Avalo Therapeutics.
InvestingPro Insights
As Avalo Therapeutics (NASDAQ: AVTX) embarks on this crucial Phase 2 clinical trial for AVTX-009, investors should be aware of some key financial metrics and insights provided by InvestingPro.
According to InvestingPro data, Avalo Therapeutics has a market capitalization of $93.27 million as of the latest available information. The company's revenue for the last twelve months as of Q2 2024 stood at $0.81 million, with a significant revenue decline of -95.24% over the same period. This substantial drop in revenue underscores the importance of the LOTUS trial's success for the company's future prospects.
InvestingPro Tips highlight that Avalo is quickly burning through cash, which is a critical factor for a biotech company in the midst of costly clinical trials. This cash burn rate emphasizes the need for the company to manage its resources efficiently as it progresses through the AVTX-009 development process.
Another relevant InvestingPro Tip indicates that analysts do not anticipate the company will be profitable this year. This aligns with the typical profile of biotech firms investing heavily in R&D and clinical trials, such as the LOTUS study for HS treatment.
It's worth noting that InvestingPro offers 11 additional tips for Avalo Therapeutics, providing a more comprehensive analysis for investors interested in delving deeper into the company's financial health and market performance.
As the LOTUS trial progresses towards its anticipated 2026 topline results, these financial insights will be crucial for investors monitoring Avalo Therapeutics' ability to fund its research and potentially bring AVTX-009 to market as a treatment for hidradenitis suppurativa.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.